Skip to content
Disclosery

ACORN CAPITAL ADVISORS, LLC

Follow

13F filer, CIK 2054410, NEW YORK, NY

ACORN CAPITAL ADVISORS, LLC reported $366,457,132 across 20 holdings for the quarter ended 2026-06-30, in a 13F-HR filed 2026-08-14. Its ten largest share positions make up 90.19% of the portfolio.

Filed (acceptance time not in the bulk data set), ingested 13F-HR 0001636587-26-000067

Period
2026-06-30
Reported value
$366M
Holdings
20
Top 10 weight
90.19%
New
1
Sold out
3

Largest buys vs the previous quarter

SecurityShares changeApprox. value
KPTIadded+1,230,287$12M
JBIOadded+200,000$4.44M
AURAadded+333,333$2.37M
ENGNnew+1,271,257$2.2M
CGONadded+999$71K

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Largest sells vs the previous quarter

SecurityShares changeApprox. value
TERNexited-1,746,264-$92.1M
BCABreduced-5,298,219-$21.9M
CRDFexited-1,762,084-$2.85M
QTTBreduced-98,881-$1.26M
X4 PHARMACEUTICALS INCexited-234,039-$967K

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Holdings, Q2 2026

Share positions as resolved from 13F-HR 0001636587-26-000067, largest first. % of portfolio is the value over $366,457,132, the sum of the share positions whose value is usable for ratios (method).

SecurityHistorySharesValue% of portfolioChangeLatest eventTimeline
CGONCG ONCOLOGY INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not loaded; 2024Q4: 1,131,501 shares; 2025Q1: 1,131,501 shares; 2025Q2: 1,131,501 shares; 2025Q3: 1,131,501 shares; 2025Q4: 1,131,501 shares; 2026Q1: 1,130,501 shares; 2026Q2: 1,131,500 shares 1,131,500$80.4M21.94%+999Timeline
URGNUROGEN PHARMA LTDQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not loaded; 2024Q4: 1,516,303 shares; 2025Q1: 1,516,303 shares; 2025Q2: 1,259,749 shares; 2025Q3: 1,259,749 shares; 2025Q4: 1,448,420 shares; 2026Q1: 1,673,420 shares; 2026Q2: 1,673,420 shares 1,673,420$61.6M16.8%0Timeline
TRVITREVI THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not loaded; 2024Q4: 2,001,048 shares; 2025Q1: 2,144,844 shares; 2025Q2: 2,144,844 shares; 2025Q3: 2,144,844 shares; 2025Q4: 2,144,844 shares; 2026Q1: 2,144,844 shares; 2026Q2: 2,144,844 shares 2,144,844$40M10.92%0Timeline
CADLCANDEL THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not loaded; 2024Q4: 1,939,644 shares; 2025Q1: 2,152,252 shares; 2025Q2: 2,580,517 shares; 2025Q3: 2,580,517 shares; 2025Q4: 2,580,517 shares; 2026Q1: 3,497,948 shares; 2026Q2: 3,497,948 shares 3,497,948$36M9.83%0Timeline
PBYIPUMA BIOTECHNOLOGY INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not loaded; 2024Q4: 3,940,052 shares; 2025Q1: 3,940,052 shares; 2025Q2: 4,131,299 shares; 2025Q3: 4,131,299 shares; 2025Q4: 4,131,299 shares; 2026Q1: 4,131,299 shares; 2026Q2: 4,131,299 shares 4,131,299$33.5M9.14%0Timeline
JBIOJADE BIOSCIENCES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not loaded; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 786,760 shares; 2026Q2: 986,760 shares 986,760$21.9M5.98%+200,000Timeline
BCAXBICARA THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not loaded; 2024Q4: 643,381 shares; 2025Q1: 643,382 shares; 2025Q2: 643,382 shares; 2025Q3: 643,382 shares; 2025Q4: 643,382 shares; 2026Q1: 643,382 shares; 2026Q2: 643,381 shares 643,381$19.1M5.21%-1Timeline
KPTIKARYOPHARM THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not loaded; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 287,826 shares; 2026Q2: 1,518,113 shares 1,518,113$14.8M4.05%+1,230,287Timeline
OKURONKURE THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not loaded; 2024Q4: 1,439,674 shares; 2025Q1: 1,439,674 shares; 2025Q2: 2,839,674 shares; 2025Q3: 2,839,674 shares; 2025Q4: 2,839,674 shares; 2026Q1: 2,839,674 shares; 2026Q2: 2,839,674 shares 2,839,674$12.9M3.53%0Timeline
HELPCYBIN INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not loaded; 2024Q4: 734,393 shares; 2025Q1: 734,394 shares; 2025Q2: 734,394 shares; 2025Q3: 734,394 shares; 2025Q4: 1,573,023 shares; 2026Q1: 1,540,266 shares; 2026Q2: 1,540,266 shares 1,540,266$10.2M2.78%0Timeline
TARAPROTARA THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not loaded; 2024Q4: 1,279,800 shares; 2025Q1: 1,279,800 shares; 2025Q2: 1,752,115 shares; 2025Q3: 1,752,115 shares; 2025Q4: 1,752,115 shares; 2026Q1: 1,752,115 shares; 2026Q2: 1,752,115 shares 1,752,115$6.69M1.83%0Timeline
AURAAURA BIOSCIENCES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not loaded; 2024Q4: not reported; 2025Q1: 590,508 shares; 2025Q2: 595,744 shares; 2025Q3: 595,744 shares; 2025Q4: 595,744 shares; 2026Q1: 595,744 shares; 2026Q2: 929,077 shares 929,077$6.6M1.8%+333,333Timeline
LONALEONABIO INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not loaded; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 501,739 shares; 2026Q1: 634,539 shares; 2026Q2: 634,539 shares 634,539$5.83M1.59%0Timeline
VSTMVERASTEM INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not loaded; 2024Q4: 779,498 shares; 2025Q1: 779,498 shares; 2025Q2: 779,498 shares; 2025Q3: 779,498 shares; 2025Q4: 1,469,153 shares; 2026Q1: 1,469,153 shares; 2026Q2: 1,469,153 shares 1,469,153$5.61M1.53%0Timeline
WHWKWHITEHAWK THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not loaded; 2024Q4: 1,147,052 shares; 2025Q1: 1,139,363 shares; 2025Q2: 1,139,363 shares; 2025Q3: 1,139,363 shares; 2025Q4: 1,139,363 shares; 2026Q1: 1,139,363 shares; 2026Q2: 1,139,363 shares 1,139,363$5.22M1.42%0Timeline
QTTBQ32 BIO INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not loaded; 2024Q4: 803,425 shares; 2025Q1: 803,425 shares; 2025Q2: 803,425 shares; 2025Q3: 803,425 shares; 2025Q4: 493,425 shares; 2026Q1: 315,052 shares; 2026Q2: 216,171 shares 216,171$2.75M0.75%-98,881Timeline
ENGNENGENE THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not loaded; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 1,271,257 shares 1,271,257$2.2M0.6%newTimeline
JSPRJASPER THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not loaded; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 1,382,640 shares; 2025Q4: 1,786,492 shares; 2026Q1: 1,411,492 shares; 2026Q2: 1,438,159 shares 1,438,159$604K0.16%+26,667Timeline
BCABBIOATLA INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not loaded; 2024Q4: 4,032,046 shares; 2025Q1: 4,032,046 shares; 2025Q2: 4,835,111 shares; 2025Q3: 4,835,111 shares; 2025Q4: 4,835,111 shares; 2026Q1: 5,406,345 shares; 2026Q2: 108,126 shares 108,126$448K0.12%-5,298,219Timeline
VYNEVYNE THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not loaded; 2024Q4: 456,970 shares; 2025Q1: 785,938 shares; 2025Q2: 736,572 shares; 2025Q3: 586,572 shares; 2025Q4: 1,425 shares; 2026Q1: 1,425 shares; 2026Q2: 1,425 shares 1,425$926<0.01%0Timeline

Sold out in Q2 2026

Positions in the previous quarter's report that this quarter's report no longer lists.

SecurityShares beforeValue beforeType
TERNTERNS PHARMACEUTICALS INC1,746,264$92.1Mshares
CRDFCARDIFF ONCOLOGY INC1,762,084$2.85Mshares
X4 PHARMACEUTICALS INCX4 PHARMACEUTICALS INC234,039$967Kshares

How Q2 2026 was built

Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).

FilingRoleAmendmentFiledAcceptedIngested
13F-HR 0001636587-26-000067 base2026-08-14acceptance time not in the bulk data set

Filings

Every filing of this filer: 13F reports and notices, the 13D and 13G it filed or is a reporting person of, and Forms 3, 4 and 5 it reported as an owner.

FilingSubjectFiledAcceptedIngested
13F-HR 0001636587-26-000067 Quarter ended 2026-06-302026-08-14acceptance time not in the bulk data set
13F-HR 0001636587-26-000029 Quarter ended 2026-03-312026-05-15acceptance time not in the bulk data set
13F-HR 0001636587-26-000005 Quarter ended 2025-12-312026-02-17acceptance time not in the bulk data set
13F-HR 0001636587-25-000060 Quarter ended 2025-09-302025-11-17acceptance time not in the bulk data set
13F-HR 0001636587-25-000043 Quarter ended 2025-06-302025-08-14acceptance time not in the bulk data set
13F-HR/A 0001636587-25-000021 Quarter ended 2025-03-312025-05-19acceptance time not in the bulk data set
13F-HR/A 0001636587-25-000020 Quarter ended 2024-12-312025-05-19acceptance time not in the bulk data set
13F-HR 0001636587-25-000017 Quarter ended 2025-03-312025-05-15acceptance time not in the bulk data set
13F-HR/A 0001636587-25-000016 Quarter ended 2024-12-312025-05-07acceptance time not in the bulk data set
13F-HR 0001636587-25-000009 Quarter ended 2024-12-312025-02-14acceptance time not in the bulk data set